menu
    • menu
    [{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Trio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"TRIObody drug conjugate","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Bio-Pharma \/ Trio Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Bio-Pharma \/ Trio Pharmaceuticals"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Bio-Pharma \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Ajinomoto Bio-Pharma \/ Humanigen"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Drugs for Neglected Disease Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"CpG-D35","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Bio-Pharma \/ Drugs for Neglected Disease Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Bio-Pharma \/ Drugs for Neglected Disease Initiative"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Daxibotulinumtoxin A","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ajinomoto Bio-Pharma \/ Revance Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Ajinomoto Bio-Pharma \/ Revance Therapeutics"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Bright Peak Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Immunocytokines","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Bio-Pharma \/ Ajinomoto","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Bio-Pharma \/ Ajinomoto"}]

    Find Clinical Drug Pipeline Developments & Deals by Ajinomoto Bio-Pharma

    Menu

    Ajinomoto Bio-Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ajinomoto Bio-Pharma

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ajinomoto Bio-Pharma

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immunocytokines

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Bright Peak Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bright Peak Therapeutics and Ajinomoto Enter into a Research Collaboration and License Agreement to Create Nov...

                            Details : As part of the collaboration and license agreement with Ajinomoto Co., the AJICAP® technology will be used to conjugate Bright Peak’s enhanced cytokines as payloads to certain antibodies, creating novel and proprietary Bright Peak Immunocytokines.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 25, 2021

                            Lead Product(s) : Immunocytokines

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Bright Peak Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ajinomoto Bio-Pharma

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ajinomoto Bio-Pharma

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daxibotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Revance Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of Daxibotu...

                            Details : Aji Bio-Pharma will operate as a dual source of supply and provide drug product manufacturing services to Revance for the supply of DaxibotulinumtoxinA for Injection at the company's aseptic manufacturing facility in San Diego, California.

                            Brand Name : DaxibotulinumtoxinA

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 22, 2020

                            Lead Product(s) : Daxibotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Revance Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ajinomoto Bio-Pharma

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ajinomoto Bio-Pharma

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CpG-D35

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Drugs for Neglected Disease Initiative

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis...

                            Details : As part of this partnership, Aji Bio-Pharma will manufacture CpG-D35, a class of CpG oligonucleotides, which provides a strong immunostimulatory effects.

                            Brand Name : CpG-D35

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 29, 2020

                            Lead Product(s) : CpG-D35

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Drugs for Neglected Disease Initiative

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ajinomoto Bio-Pharma

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ajinomoto Bio-Pharma

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Humanigen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab

                            Details : Aji Bio Pharma will provide drug product aseptic fill finish services for Humanigen. Lenzilumab, Humanigen’s Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody is being administered as part of a Phase III study...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 27, 2020

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Humanigen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ajinomoto Bio-Pharma

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ajinomoto Bio-Pharma

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRIObody drug conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Trio Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services Enter into a Development Collaboration for a Nove...

                            Details : Trio Pharmaceuticals and Ajinomoto Bio-Pharma Services will evaluate AJICAP™, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDCs.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 30, 2020

                            Lead Product(s) : TRIObody drug conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Trio Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth